{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T13:29:14Z","timestamp":1786627754010,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["UMO-2020\/39\/D\/NZ7\/00149"],"award-info":[{"award-number":["UMO-2020\/39\/D\/NZ7\/00149"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Gastrointestinal (GI) tract diseases cause symptoms that significantly affect the quality of life. A promising direction in the search for novel therapeutic options in this field is the investigation of G protein-coupled receptors (GPCRs), whose activity is modulated by their regulator proteins (RGS). In this study, we examined RGS6 involvement in GI inflammation and functional disorders and its effect on cannabinoid (CB), opioid, and serotonin receptor (5HTR)-targeting compounds,<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using quantitative PCR, western blot, and ELISA assays, we characterized RGS6 expression in the mouse GI tract and measured GPCR-related secondary messenger expression upon stimulation with GPCR agonists in vitro in Caco-2 cells, both wild type (WT) and RGS6 knock-out (KO). Then, in vivo in a dextran sulfate sodium (DSS) mouse model of colitis using WT, global and tissue-specific RGS6 KO mice, inflammation, antinociceptive effects, and GI motility were examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In Caco-2 cells, we found that RGS6 KO increased extracellular signal-regulated kinase phosphorylation, which was blocked by CB agonist WIN 55,212-2. Moreover, incubation with WIN 55,212-2 significantly reduced cyclic adenosine monophosphate (cAMP) levels in RGS6 KO but not WT cells. In DSS-induced, acute and chronic-relapsing mouse models of colitis, RGS6 KO resulted in resistance to stress-induced GI hypermotility. WIN 55,212-2 (1\u00a0mg\/kg ip) substantially prolonged GI transit time and displayed antinociceptive properties that were stronger in the absence of RGS6. Epithelial -specific RGS6 KO did not affect the action of WIN 55,212-2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>RGS6 exerts crucial effects on GI physiology by acting on CB signaling in the enteric and\/or central nervous system.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s43440-026-00887-x","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T12:35:22Z","timestamp":1786624522000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Regulator of G protein signaling 6 (RGS6) controls the effect of cannabinoids on intestinal tract motility and visceral pain sensation in mice"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3066-8880","authenticated-orcid":false,"given":"Miko\u0142aj","family":"\u015awierczy\u0144ski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Makaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Jaczy\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Sobalska-Kwapis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Seweryn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna","family":"Kasprzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Tarasiuk-Zawadzka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5917-8749","authenticated-orcid":false,"given":"Maciej","family":"Sa\u0142aga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"887_CR1","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrgastro.2015.34","volume":"12","author":"AN Ananthakrishnan","year":"2015","unstructured":"Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12:205\u201317. https:\/\/doi.org\/10.1038\/nrgastro.2015.34.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"887_CR2","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S2468-1253(19)30089-5","volume":"4","author":"DJ Gracie","year":"2019","unstructured":"Gracie DJ, Hamlin PJ, Ford AC. The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment. Lancet Gastroenterol Hepatol. 2019;4:632\u201342. https:\/\/doi.org\/10.1016\/S2468-1253(19)30089-5.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"887_CR3","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1080\/15548627.2016.1235125","volume":"12","author":"PM Coly","year":"2016","unstructured":"Coly PM, Perzo N, Le Joncour V, Lecointre C, Schouft MT, Desrues L, et al. Chemotactic G protein-coupled receptors control cell migration by repressing autophagosome biogenesis. Autophagy. 2016;12:2344\u201362. https:\/\/doi.org\/10.1080\/15548627.2016.1235125.","journal-title":"Autophagy"},{"key":"887_CR4","doi-asserted-by":"publisher","unstructured":"Swierczynski M, Kasprzak Z, Makaro A, Salaga M. Regulators of G-protein signaling (RGS) in sporadic and colitis-associated colorectal cancer. Int J Mol Sci. 2024;25. https:\/\/doi.org\/10.3390\/ijms25010577.","DOI":"10.3390\/ijms25010577"},{"key":"887_CR5","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1053\/j.gastro.2019.01.266","volume":"156","author":"M Canals","year":"2019","unstructured":"Canals M, Poole DP, Veldhuis NA, Schmidt BL, Bunnett NW. G-Protein\u2013Coupled Receptors Are Dynamic Regulators of Digestion and Targets for Digestive Diseases. Gastroenterology. 2019;156:1600\u201316. https:\/\/doi.org\/10.1053\/j.gastro.2019.01.266.","journal-title":"Gastroenterology"},{"key":"887_CR6","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrgastro.2013.105","volume":"10","author":"GM Mawe","year":"2013","unstructured":"Mawe GM, Hoffman JM. Serotonin signalling in the gut\u2014functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol. 2013;10:473\u201386. https:\/\/doi.org\/10.1038\/nrgastro.2013.105.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"887_CR7","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1177\/0192623316679898","volume":"45","author":"F Wang","year":"2017","unstructured":"Wang F, Roy S. Gut Homeostasis, Microbial Dysbiosis, and Opioids. Toxicol Pathol. 2017;45:150\u20136. https:\/\/doi.org\/10.1177\/0192623316679898.","journal-title":"Toxicol Pathol"},{"key":"887_CR8","doi-asserted-by":"publisher","unstructured":"Crowley K, Kiraga \u0141, Miszczuk E, Skiba S, Banach J, Latek U, et al. Effects of cannabinoids on intestinal motility, barrier permeability, and therapeutic potential in gastrointestinal diseases. Int J Mol Sci. 2024;25. https:\/\/doi.org\/10.3390\/ijms25126682.","DOI":"10.3390\/ijms25126682"},{"key":"887_CR9","doi-asserted-by":"publisher","unstructured":"Chaudhary PK, Kim S. An insight into GPCR and G-proteins as cancer drivers. Cells. 2021;10. https:\/\/doi.org\/10.3390\/cells10123288","DOI":"10.3390\/cells10123288"},{"key":"887_CR10","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.bbamem.2006.10.021","volume":"1768","author":"BK Kobilka","year":"2007","unstructured":"Kobilka BK. G protein coupled receptor structure and activation. Biochim Biophys Acta. 2007;1768:794\u2013807. https:\/\/doi.org\/10.1016\/j.bbamem.2006.10.021.","journal-title":"Biochim Biophys Acta"},{"key":"887_CR11","doi-asserted-by":"publisher","unstructured":"Ahlers-Dannen KE, Alqinyah M, Bodle C, Bou Dagher J, Chakravarti B, Choudhuri SP, et al. Regulators of G protein signaling (RGS) proteins in GtoPdb v.2021.2. IUPHAR\/BPS Guide to Pharmacology CITE. 2021;2021. https:\/\/doi.org\/10.2218\/gtopdb\/F891\/2021.2.","DOI":"10.2218\/gtopdb\/F891\/2021.2"},{"key":"887_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s10038-024-01220-1","volume":"69","author":"KE Ahlers-Dannen","year":"2024","unstructured":"Ahlers-Dannen KE, Yang J, Spicer MM, Fu D, DeVore A, Fisher RA. A splice acceptor variant in RGS6 associated with intellectual disability, microcephaly, and cataracts disproportionately promotes expression of a subset of RGS6 isoforms. J Hum Genet. 2024;69:145\u201352. https:\/\/doi.org\/10.1038\/s10038-024-01220-1.","journal-title":"J Hum Genet"},{"key":"887_CR13","doi-asserted-by":"publisher","unstructured":"Ahlers-Dannen KE, Yang J, Spicer MM, Maity B, Stewart A, Koland JG, et al. Protein profiling of RGS6, a pleiotropic gene implicated in numerous neuropsychiatric disorders, reveals multi-isoformic expression and a novel brain-specific isoform. ENeuro. 2022;9. https:\/\/doi.org\/10.1523\/ENEURO.0379-21.2021.","DOI":"10.1523\/ENEURO.0379-21.2021"},{"key":"887_CR14","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/j.tiv.2010.04.002","volume":"24","author":"J Van De Walle","year":"2010","unstructured":"Van De Walle J, Hendrickx A, Romier B, Larondelle Y, Schneider Y-J. Inflammatory parameters in Caco-2 cells: effect of stimuli nature, concentration, combination and cell differentiation. Toxicol Vitro. 2010;24:1441\u20139. https:\/\/doi.org\/10.1016\/j.tiv.2010.04.002.","journal-title":"Toxicol Vitro"},{"key":"887_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejphar.2018.08.016","volume":"836","author":"M Salaga","year":"2018","unstructured":"Salaga M, Binienda A, Tichkule RB, Thakur GA, Makriyannis A, Storr M, et al. The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome. Eur J Pharmacol. 2018;836:34\u201343. https:\/\/doi.org\/10.1016\/j.ejphar.2018.08.016.","journal-title":"Eur J Pharmacol"},{"key":"887_CR16","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1124\/jpet.117.242586","volume":"363","author":"M Salaga","year":"2017","unstructured":"Salaga M, Mokrowiecka A, Zielinska M, Malecka-Panas E, Kordek R, Kamysz E, et al. New Peptide Inhibitor of Dipeptidyl Peptidase IV, EMDB-1 Extends the Half-Life of GLP-2 and Attenuates Colitis in Mice after Topical Administration. J Pharmacol Exp Ther. 2017;363:92\u2013103. https:\/\/doi.org\/10.1124\/jpet.117.242586.","journal-title":"J Pharmacol Exp Ther"},{"key":"887_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.bcp.2019.01.001","volume":"161","author":"M Salaga","year":"2019","unstructured":"Salaga M, Binienda A, Piscitelli F, Mokrowiecka A, Cygankiewicz AI, Verde R, et al. Systemic administration of serotonin exacerbates abdominal pain and colitis via interaction with the endocannabinoid system. Biochem Pharmacol. 2019;161:37\u201351. https:\/\/doi.org\/10.1016\/j.bcp.2019.01.001.","journal-title":"Biochem Pharmacol"},{"key":"887_CR18","doi-asserted-by":"publisher","first-page":"100876","DOI":"10.1016\/j.phyplu.2025.100876","volume":"5","author":"M Barakat","year":"2025","unstructured":"Barakat M, Thiab S, Alzaghari LF, Abdulrazzaq SB, Hasen E, Abuarab SF, et al. Cannabis and the immune response: A comprehensive review of therapeutic potential and concerns. Phytomedicine Plus. 2025;5:100876. https:\/\/doi.org\/10.1016\/j.phyplu.2025.100876.","journal-title":"Phytomedicine Plus"},{"key":"887_CR19","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1016\/j.cgh.2023.07.031","volume":"21","author":"M Camilleri","year":"2023","unstructured":"Camilleri M, Zheng T. Cannabinoids and the Gastrointestinal Tract. Clin Gastroenterol Hepatol. 2023;21:3217\u201329. https:\/\/doi.org\/10.1016\/j.cgh.2023.07.031.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"887_CR20","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/MIB.0000000000001004","volume":"23","author":"KL Leinwand","year":"2017","unstructured":"Leinwand KL, Gerich ME, Hoffenberg EJ, Collins CB. Manipulation of the Endocannabinoid System in Colitis. Inflamm Bowel Dis. 2017;23:192\u20139. https:\/\/doi.org\/10.1097\/MIB.0000000000001004.","journal-title":"Inflamm Bowel Dis"},{"key":"887_CR21","doi-asserted-by":"publisher","first-page":"G364","DOI":"10.1152\/ajpgi.00407.2005","volume":"291","author":"ES Kimball","year":"2006","unstructured":"Kimball ES, Schneider CR, Wallace NH, Hornby PJ. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiology-Gastrointestinal Liver Physiol. 2006;291:G364\u201371. https:\/\/doi.org\/10.1152\/ajpgi.00407.2005.","journal-title":"Am J Physiology-Gastrointestinal Liver Physiol"},{"key":"887_CR22","doi-asserted-by":"publisher","first-page":"e6893","DOI":"10.1371\/journal.pone.0006893","volume":"4","author":"L Marqu\u00e9z","year":"2009","unstructured":"Marqu\u00e9z L, Su\u00e1rez J, Iglesias M, Bermudez-Silva FJ, Rodr\u00edguez de Fonseca F, Andreu M. Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue. PLoS ONE. 2009;4:e6893. https:\/\/doi.org\/10.1371\/journal.pone.0006893.","journal-title":"PLoS ONE"},{"key":"887_CR23","doi-asserted-by":"publisher","first-page":"e13370","DOI":"10.1111\/nmo.13370","volume":"30","author":"M Camilleri","year":"2018","unstructured":"Camilleri M. Cannabinoids and gastrointestinal motility: Pharmacology, clinical effects, and potential therapeutics in humans. Neurogastroenterol Motil. 2018;30:e13370. https:\/\/doi.org\/10.1111\/nmo.13370.","journal-title":"Neurogastroenterol Motil"},{"key":"887_CR24","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1161\/CIRCRESAHA.110.224220","volume":"107","author":"J Yang","year":"2010","unstructured":"Yang J, Huang J, Maity B, Gao Z, Lorca RA, Gudmundsson H, et al. RGS6, a modulator of parasympathetic activation in heart. Circ Res. 2010;107:1345\u20139. https:\/\/doi.org\/10.1161\/CIRCRESAHA.110.224220.","journal-title":"Circ Res"},{"key":"887_CR25","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1208\/s12248-016-9899-9","volume":"18","author":"KE Ahlers","year":"2016","unstructured":"Ahlers KE, Chakravarti B, Fisher RA. RGS6 as a Novel Therapeutic Target in CNS Diseases and Cancer. AAPS J. 2016;18:560\u201372. https:\/\/doi.org\/10.1208\/s12248-016-9899-9.","journal-title":"AAPS J"},{"key":"887_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3233\/CBM-203259","volume":"32","author":"B Kang","year":"2021","unstructured":"Kang B, Lee HS, Jeon SW, Park SY, Choi GS, Lee WK, et al. Progressive alteration of DNA methylation of Alu, MGMT, MINT2, and TFPI2 genes in colonic mucosa during colorectal cancer development. Cancer Biomark. 2021;32:231\u20136. https:\/\/doi.org\/10.3233\/CBM-203259.","journal-title":"Cancer Biomark"},{"key":"887_CR27","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s00424-018-2187-z","volume":"470","author":"I Romero-Calvo","year":"2018","unstructured":"Romero-Calvo I, Oc\u00f3n B, G\u00e1mez-Belmonte R, Hern\u00e1ndez-Chirlaque C, de Jonge HR, Bijvelds MJ, et al. Adenylyl cyclase 6 is involved in the hyposecretory status of experimental colitis. Pflugers Arch. 2018;470:1705\u201317. https:\/\/doi.org\/10.1007\/s00424-018-2187-z.","journal-title":"Pflugers Arch"},{"key":"887_CR28","doi-asserted-by":"publisher","unstructured":"Leo LM, Abood ME. CB1 Cannabinoid receptor signaling and biased signaling. Molecules. 2021;26. https:\/\/doi.org\/10.3390\/molecules26175413.","DOI":"10.3390\/molecules26175413"},{"key":"887_CR29","doi-asserted-by":"publisher","first-page":"7963","DOI":"10.3892\/mmr.2015.4477","volume":"12","author":"D XU","year":"2015","unstructured":"Xu D, Wang J, Zhou Z, He ZZ. Cannabinoid WIN55, 212-2 induces cell cycle arrest and inhibits the proliferation and migration of human BEL7402 hepatocellular carcinoma cells. Mol Med Rep. 2015;12:7963\u201370. https:\/\/doi.org\/10.3892\/mmr.2015.4477.","journal-title":"Mol Med Rep"},{"key":"887_CR30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.brainres.2012.11.006","volume":"WIN55","author":"J Sun","year":"2013","unstructured":"Sun J, Fang Y, Chen T, Guo J, Yan J, Song S, et al. 212-2 promotes differentiation of oligodendrocyte precursor cells and improve remyelination through regulation of the phosphorylation level of the ERK 1\/2 via cannabinoid receptor 1 after stroke-induced demyelination. Brain Res. 2013;WIN55:1491:225\u201335. https:\/\/doi.org\/10.1016\/j.brainres.2012.11.006.","journal-title":"Brain Res"},{"key":"887_CR31","doi-asserted-by":"publisher","unstructured":"Jain R, Watson U, Vasudevan L, Saini DK. ERK Activation pathways downstream of GPCRs. Int Rev Cell Mol Biol. 2018;338:79\u2013109. https:\/\/doi.org\/10.1016\/bs.ircmb.2018.02.003.","DOI":"10.1016\/bs.ircmb.2018.02.003"},{"key":"887_CR32","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/S1470-2045(05)70168-6","volume":"6","author":"JY Fang","year":"2005","unstructured":"Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 2005;6:322\u20137. https:\/\/doi.org\/10.1016\/S1470-2045(05)70168-6.","journal-title":"Lancet Oncol"},{"key":"887_CR33","doi-asserted-by":"publisher","unstructured":"Stefani C, Miricescu D, Stanescu-Spinu I-I, Nica RI, Greabu M, Totan AR, et al. Growth factors, PI3K\/AKT\/mTOR and MAPK signaling pathways in colorectal cancer pathogenesis: Where are we now? Int J Mol Sci. 2021;22. https:\/\/doi.org\/10.3390\/ijms221910260.","DOI":"10.3390\/ijms221910260"},{"key":"887_CR34","doi-asserted-by":"publisher","first-page":"176166","DOI":"10.1016\/j.ejphar.2023.176166","volume":"960","author":"HS Althagafy","year":"2023","unstructured":"Althagafy HS, Ali FEM, Hassanein EHM, Mohammedsaleh ZM, Kotb El-Sayed MI, Atwa AM, et al. Canagliflozin ameliorates ulcerative colitis via regulation of TLR4\/MAPK\/NF-\u03baB and Nrf2\/PPAR-\u03b3\/SIRT1 signaling pathways. Eur J Pharmacol. 2023;960:176166. https:\/\/doi.org\/10.1016\/j.ejphar.2023.176166.","journal-title":"Eur J Pharmacol"},{"key":"887_CR35","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1080\/15384101.2022.2100682","volume":"21","author":"F Izadparast","year":"2022","unstructured":"Izadparast F, Riahi-Zajani B, Yarmohammadi F, Hayes AW, Karimi G. Protective effect of berberine against LPS-induced injury in the intestine: a review. Cell Cycle. 2022;21:2365\u201378. https:\/\/doi.org\/10.1080\/15384101.2022.2100682.","journal-title":"Cell Cycle"},{"key":"887_CR36","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2018.8397","author":"M Li","year":"2018","unstructured":"Li M, Qian X, Zhu M, Li A, Fang M, Zhu Y, et al. miR-1273\u00a0g-3p promotes proliferation, migration and invasion of LoVo cells via cannabinoid receptor 1 through activation of ERBB4\/PIK3R3\/mTOR\/S6K2 signaling pathway. Mol Med Rep. 2018. https:\/\/doi.org\/10.3892\/mmr.2018.8397.","journal-title":"Mol Med Rep"},{"key":"887_CR37","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/pros.23720","volume":"55","author":"D Roberto","year":"2019","unstructured":"Roberto D, Klotz LH, Venkateswaran V, Cannabinoid WIN. 212-2 induces cell cycle arrest and apoptosis, and inhibits proliferation, migration, invasion, and tumor growth in prostate cancer in a cannabinoid-receptor 2 dependent manner. Prostate. 2019;55:79:151\u20139. https:\/\/doi.org\/10.1002\/pros.23720.","journal-title":"Prostate"},{"key":"887_CR38","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.brainres.2018.04.023","volume":"1692","author":"J Matsumoto","year":"2018","unstructured":"Matsumoto J, Dohgu S, Takata F, Machida T, B\u00f6l\u00fckba\u015fi Hatip FF, Hatip-Al-Khatib I, et al. TNF-\u03b1-sensitive brain pericytes activate microglia by releasing IL-6 through cooperation between I\u03baB-NF\u03baB and JAK-STAT3 pathways. Brain Res. 2018;1692:34\u201344. https:\/\/doi.org\/10.1016\/j.brainres.2018.04.023.","journal-title":"Brain Res"},{"key":"887_CR39","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/08977190701830151","volume":"25","author":"H Kiu","year":"2007","unstructured":"Kiu H, Hilton DJ, Nicola NA, Ernst M, Marquez R, Alexander WS, et al. Mechanism of crosstalk inhibition of IL-6 signaling in response to LPS and TNFalpha. Growth Factors. 2007;25:319\u201328. https:\/\/doi.org\/10.1080\/08977190701830151.","journal-title":"Growth Factors"},{"key":"887_CR40","doi-asserted-by":"publisher","first-page":"35797","DOI":"10.1074\/jbc.M507959200","volume":"280","author":"NM Curran","year":"2005","unstructured":"Curran NM, Griffin BD, O\u2019Toole D, Brady KJ, Fitzgerald SN, Moynagh PN. The synthetic cannabinoid R(+)WIN 55,212-2 inhibits the interleukin-1 signaling pathway in human astrocytes in a cannabinoid receptor-independent manner. J Biol Chem. 2005;280:35797\u2013806. https:\/\/doi.org\/10.1074\/jbc.M507959200.","journal-title":"J Biol Chem"},{"key":"887_CR41","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1096\/fj.13-235648","volume":"28","author":"A Stewart","year":"2014","unstructured":"Stewart A, Maity B, Wunsch AM, Meng F, Wu Q, Wemmie JA, et al. Regulator of G-protein signaling 6 (RGS6) promotes anxiety and depression by attenuating serotonin\u2010mediated activation of the 5\u2010HT 1A receptor\u2010adenylyl cyclase axis. FASEB J. 2014;28:1735\u201344. https:\/\/doi.org\/10.1096\/fj.13-235648.","journal-title":"FASEB J"},{"key":"887_CR42","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.neuropharm.2018.07.028","volume":"140","author":"TD Nissen","year":"2018","unstructured":"Nissen TD, Brock C, Lykkesfeldt J, Lindstr\u00f6m E, Hultin L. Pharmacological modulation of colorectal distension evoked potentials in conscious rats. Neuropharmacology. 2018;140:193\u2013200. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.07.028.","journal-title":"Neuropharmacology"},{"key":"887_CR43","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1124\/jpet.114.214239","volume":"350","author":"M Sa\u0142aga","year":"2014","unstructured":"Sa\u0142aga M, Polepally PR, Sobczak M, Grzywacz D, Kamysz W, Sibaev A, et al. Novel orally available salvinorin A analog PR-38 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome. J Pharmacol Exp Ther. 2014;350:69\u201378. https:\/\/doi.org\/10.1124\/jpet.114.214239.","journal-title":"J Pharmacol Exp Ther"},{"key":"887_CR44","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.bcp.2014.09.018","volume":"92","author":"M Sa\u0142aga","year":"2014","unstructured":"Sa\u0142aga M, Polepally PR, Zakrzewski PK, Cygankiewicz A, Sobczak M, Kordek R, et al. Novel orally available salvinorin A analog PR-38 protects against experimental colitis and reduces abdominal pain in mice by interaction with opioid and cannabinoid receptors. Biochem Pharmacol. 2014;92:618\u201326. https:\/\/doi.org\/10.1016\/j.bcp.2014.09.018.","journal-title":"Biochem Pharmacol"},{"key":"887_CR45","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/nmo.12272","volume":"26","author":"J Fichna","year":"2014","unstructured":"Fichna J, Sa\u0142aga M, Stuart J, Saur D, Sobczak M, Zatorski H, et al. Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides. Neurogastroenterol Motil. 2014;26:470\u201381. https:\/\/doi.org\/10.1111\/nmo.12272.","journal-title":"Neurogastroenterol Motil"},{"key":"887_CR46","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s00210-015-1142-1","volume":"388","author":"M Sa\u0142aga","year":"2015","unstructured":"Sa\u0142aga M, Kowalczuk A, Zielinska M, B\u0142a\u017cewicz A, Fichna J. Calea zacatechichi dichloromethane extract exhibits antidiarrheal and antinociceptive effects in mouse models mimicking irritable bowel syndrome. Naunyn Schmiedebergs Arch Pharmacol. 2015;388:1069\u201377. https:\/\/doi.org\/10.1007\/s00210-015-1142-1.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00887-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-026-00887-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00887-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T12:35:23Z","timestamp":1786624523000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-026-00887-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":46,"alternative-id":["887"],"URL":"https:\/\/doi.org\/10.1007\/s43440-026-00887-x","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"26 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal protocols were approved by the Medical University of Lodz Animal Care Committee (31\/\u0141B205\/2021).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}